New hope for rare cancers: targeted drug trial now recruiting
NCT ID NCT05745623
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 30 times
Summary
This study tests an experimental drug called ICP-723 in people whose advanced solid tumors or brain tumors have a specific genetic change called NTRK fusion. About 70 participants will receive the drug to see if it shrinks tumors or slows their growth. The goal is to find a new treatment option for these hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS HARBORING NTRK FUSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Conditions
Explore the condition pages connected to this study.